Literature DB >> 1141431

Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.

L H Perrin, P H Lambert, P A Miescher.   

Abstract

A dynamic estimation of the involvement of the complement system in various diseases was obtained by the direct quantitation of breakdown products of C3 and of properdin factor B. The methods used were based, first on the separation of native and fragmented molecules according to their molecular size through a precipitation with polyethylene glycol and, secondly, on an immunochemical quantitation, using specific antisera for the major antigens of C3 and factor B. The sensitivity and the specificity of these methods were demonstrated by activation of complement in vitro with generation of C3 and factor B fragments. A clinical investigation was carried out in 41 patients with systemic lupus erythematosus (SLE), 31 with membranoproliferative glomerulonephritis (MPGN), 26 with other types of glomerulonephritis, and 6 with severe alcoholic cirrhosis of the liver. The following observations were made: (a) an elevated plasma level of C3d fragment of C3 was found in 68% of SLE patients, in 87% of MPGN patients, in 62% of patients with other hypocomplementemic nephritis, and in 15% of those with normocomplementemic nephritis, but in only 33% of patients with liver cirrhosis and very low levels of C3; (b) a significant difference was observed between the levels of C3 obtained with either anti-"native" C3 or anti-C3c sera for immunochemical quantitation, in patients with SLE or MPGN, indicating the presence of "altered" or fragmented C3 in plasma; (c) an elevated plasma level of Ba fragment of properdin factor B was found in 46% of SLE patients, in 67% of MPGN patients, in 50% of patients with other hypocomplementemic nephritis, and in 9% of patients with normocomplementemic nephritis, while the level of properdin factor B was only slightly decreased in these diseases; (d) in SLE and MPGN there was an inverse correlation between the levels of C3d and Ba and the level of C3 in plasma. The level of these fragments was directly correlated with the clinical manifestations of SLE; (e) some patients with a normal C3 level exhibited an elevated plasma concentration of C3 and factor B fragments, suggesting the coexistence of an increased synthesis with a hypercatabolism of complement components. Therefore, the quantitation of complement breakdown products by simple immunochemical methods provides additional information concerning the involvement of complement in disease and new features for the evaluation of the intensity of immune reactions during immune complex diseases.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1141431      PMCID: PMC436567          DOI: 10.1172/JCI108065

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  26 in total

1.  The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena.

Authors:  L PILLEMER; L BLUM; I H LEPOW; O A ROSS; E W TODD; A C WARDLAW
Journal:  Science       Date:  1954-08-20       Impact factor: 47.728

2.  Anti-nuclear factors and serum complement in systemic lupus erythematosus.

Authors:  J H MORSE; H J MULLER-EBERHARD; H G KUNKEL
Journal:  Bull N Y Acad Med       Date:  1962-10

3.  Detection of antibodies and soluble antigen-antibody complexes by precipitation with polyethylene glycol.

Authors:  W D Creighton; P H Lambert; P A Miescher
Journal:  J Immunol       Date:  1973-10       Impact factor: 5.422

4.  Alternate complement pathway: factors involved in cobra venom factor (CoVF) activation of the third component of complement (C3).

Authors:  L G Hunsicker; S Ruddy; K F Austen
Journal:  J Immunol       Date:  1973-01       Impact factor: 5.422

5.  The complement system of man. 3.

Authors:  S Ruddy; I Gigli; K F Austen
Journal:  N Engl J Med       Date:  1972-09-21       Impact factor: 91.245

6.  Decreased synthesis of the third component of complement (C3) in hypocomplementemic systemic lupus erythematosus.

Authors:  A J Sliwinski; N J Zvaifler
Journal:  Clin Exp Immunol       Date:  1972-05       Impact factor: 4.330

7.  Studies of the third component of complement in synovial fluid from arthritic patients. II. Conversion and its relation to total complement.

Authors:  H Hedberg; B Lundh; A B Laurell
Journal:  Clin Exp Immunol       Date:  1970-05       Impact factor: 4.330

8.  Alper CA, Rosen FS: Studies of the in vivo behavior of human C'3 in normal subjects and patients.

Authors:  C A Alper; F S Rosen
Journal:  J Clin Invest       Date:  1967-12       Impact factor: 14.808

9.  ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT.

Authors:  U R NILSSON; H J MUELLER-EBERHARD
Journal:  J Exp Med       Date:  1965-08-01       Impact factor: 14.307

10.  Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum.

Authors:  V A Bokisch; H J Müller-Eberhard; C G Cochrane
Journal:  J Exp Med       Date:  1969-05-01       Impact factor: 14.307

View more
  69 in total

1.  Immune complexes and complement hypercatabolism in patients with leprosy.

Authors:  B Bjorvatn; R S Barnetson; G Kronvall; R H Zubler; P H Lambert
Journal:  Clin Exp Immunol       Date:  1976-12       Impact factor: 4.330

Review 2.  Review: assessment of complement activation in clinical immunology laboratories: time for reappraisal?

Authors:  M Peakman; G Senaldi; D Vergani
Journal:  J Clin Pathol       Date:  1989-10       Impact factor: 3.411

3.  Experimental lupus nephritis in severe combined immunodeficient (SCID) mice: remodelling of the glomerular lesions by bystander IgM antibodies.

Authors:  M R Ito; S Terasaki; E Kondo; H Shiwaku; Y Fukuoka; M Nose
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

4.  Complement activation profiles in disease.

Authors:  D L Brown
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1979

5.  Activation of peripheral blood lymphocytes in patients with primary Sjögren's syndrome.

Authors:  P Youinou; Y L Pennec; M A Blaschek; A Gentric; J Jouquan; A Lamour; P Angelidis
Journal:  Rheumatol Int       Date:  1988       Impact factor: 2.631

6.  Evaluation of plasma C3d and immune complex determinations in the assessment of disease activity of patients with rheumatoid arthritis, systemic lupus erythematosus, and spondylitis ancylopoetica.

Authors:  P B Krauledat; F E Krapf; B Manger; J R Kalden
Journal:  Rheumatol Int       Date:  1985       Impact factor: 2.631

7.  Polyclonal B cell activation, circulating immune complexes and autoimmunity in human american visceral leishmaniasis.

Authors:  B Galvão-Castro; J A Sá Ferreira; K F Marzochi; M C Marzochi; S G Coutinho; P H Lambert
Journal:  Clin Exp Immunol       Date:  1984-04       Impact factor: 4.330

8.  Circulating antigens, immune complexes and C3d levels in human schistosomiasis: relationship with Schistosoma mansoni egg output.

Authors:  F Santoro; A Prata; C N Castro; A Capron
Journal:  Clin Exp Immunol       Date:  1980-11       Impact factor: 4.330

9.  Magnitude of bacteremia and complement activation during Neisseria meningitidis infection: study of two co-primary cases with different clinical presentations.

Authors:  A Zwahlen; F A Waldvogel
Journal:  Eur J Clin Microbiol       Date:  1984-10       Impact factor: 3.267

10.  Combined steroid-cyclosporin treatment of chronic autoimmune diseases. Clinical results and assessment of nephrotoxicity by renal biopsy.

Authors:  P A Miescher; H Favre; F Chatelanat; M J Mihatsch
Journal:  Klin Wochenschr       Date:  1987-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.